The fact that the infusion of the phosphodiesterase type 5 inhibitor, zaprinast, restored D1 receptors in tubular cells, cGMP urinary excretion, and natriuresis to control levels supports the hypothesis of a dysfunction in ANP and D1 receptors in nephrotic syndrome [51]. This evidence concerns the gene NPPA and nephrotic syndrome.